Winship researchers will present abstracts and discuss their latest practice-changing work at the 45th San Antonio Breast Cancer Symposium in San Antonio, Dec. 6-10, 2022.
Researchers from Winship Cancer Institute of Emory University will present abstracts and discuss their latest practice-changing work at the 45th San Antonio Breast Cancer Symposium in San Antonio, Dec. 6-10, 2022.
Co-sponsored by the American Association for Cancer Research and the Mays Cancer Center at UT Health San Antonio, the annual symposium brings together about 10,000 clinicians and scientists and is the largest scientific gathering on breast cancer research.
"There are a number of practice-changing data being presented at the 2022 San Antonio Breast Cancer Symposium," said Kevin Kalinsky, MD, MS, director of the Glenn Family Breast Center at Winship. "The active research within the Glenn Family Breast Center is being well-represented in the various high-impact presentations at the meeting."
At the 2021 San Antonio Breast Cancer Symposium, Kalinsky and colleagues presented initial results from the RxPONDER study (SWOG S1007). The national study, which was led by Kalinsky and published in the New England Journal of Medicine, found that postmenopausal women with certain types of breast cancer can forgo chemotherapy. This year, Kalinsky and RxPONDER investigators will present three abstracts with updates on patient-reported symptoms and race and clinical outcomes of women who participated in the trial. One abstract reports findings that Black women with HR+/HER2- breast cancer have worse outcomes than all racial and ethnic groups with the same diagnosis.
Winship researchers will participate in 35 presentations as session chairs, oral and poster presenters, speakers and collaborators on multi-institutional studies. Sessions will highlight groundbreaking clinical trials, novel treatment combinations, immune-based therapies, health disparities and outcomes research and advances in how we understand and treat breast cancer subtypes, including HER2 low and triple negative breast cancer.
View the full schedule of Winship presentations at the San Antonio Breast Cancer Symposium.
